Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly

References

• Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol.21, 1383–1389 (2003).
   PubMed Web of Science ®Google Scholar
• Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann. Intern. Med.120, 104–110 (1994).
   PubMed Web of Science ®Google Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst.92, 550–556 (2000).
   PubMed Web of Science ®Google Scholar
• Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women 65 years. Br. J. Cancer96, 1197–1203 (2007).
   PubMedGoogle Scholar
• Bouchardy C, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J. Clin. Oncol.21, 3580–3587 (2003).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2, 127–37 (2001).
   PubMed Web of Science ®Google Scholar
• Hannahan D, Weinberg R. The hallmarks of cancer. Br. J. Cancer100, 680–683 (2009).
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2–2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br. J. Cancer100, 680–683 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas GA, Leonard RC. How age affects the biology of breast cancer. Clin. Oncol.21, 81–85 (2009).
   Web of Science ®Google Scholar
• Mustacchi G, Cazzaniga ME, Pronzato P et al. Breast cancer in elderly women: a different reality? Results from the NORA study. Ann. Oncol.18, 991–996 (2007).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet20, 1687–1717 (2005).
   Google Scholar
• Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J. Clin. Oncol.24, 2750–2756 (2006).
   PubMed Web of Science ®Google Scholar
• Fargeot P, Bonneterre J, Roache H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatement of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 Trial. J. Clin. Oncol.22, 4674–4682 (2004).
   Google Scholar
• Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J. Clin. Oncol.18, 1412–1422 (2000).
   PubMed Web of Science ®Google Scholar
• Muss H, Berry D, Cirrincione C et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N. Engl. J. Med.360, 2055–65 (2009).
   PubMed Web of Science ®Google Scholar
• Nuzzo F, Morabito A, De Maio E et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre Phase 3 randomised ELDA trial. Crit. Rev. Oncol. Hematol.66, 171–180 (2008).
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan K-H, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6, 117–127 (2004).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6, 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Slamon D, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet369, 29–36 (2007).
   PubMed Web of Science ®Google Scholar
• Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann. Oncol.19, 1090–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Takita M, Matsumura T, Kodama Y, Tanaka Y, Kami M. Trastuzumab after adjuvant chemotherapy in older patients. Lancet369, 991–992 (2007).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokempu-Lehtinen P-L, Bono P et al. Adjuvant doctaxel of vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354, 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roche´H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol.27, 6129–6134 (2009).
   PubMed Web of Science ®Google Scholar
• Suter T, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial. J. Clin. Oncol.25, 1–8 (2007).
   PubMedGoogle Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9, 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• BIG 1–98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med.361, 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Carlomagno C, Perrone F, Gallo C et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol.10, 2702–2708 (1996).
   Google Scholar
• Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. J. Clin. Oncol.26, 1059–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol.21(10), 1967–1972 (2003).
   PubMed Web of Science ®Google Scholar
• Kunisue H, Kurebayashi J, Otsuki T et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br. J. Cancer82(1), 46–51 (2000).
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey J, Clemens M et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor–positive metastatic breast cancer: results from the randomized Phase III TAnDEM study. J. Clin. Oncol.27, 5492–5494 (2009).
   PubMedGoogle Scholar